Roberto Galli

Finanzdirektor/CFO bei NEWRON PHARMACEUTICALS S.P.A.

Commercial Services

Health Technology

Consumer Services

Profil

Roberto Galli currently works at Newron Sweden AB, as Director, Newron Pharmaceuticals US, Inc., as Secretary, Treasurer & Director, and Newron Pharmaceuticals SpA, as Chief Financial Officer from 2023.
Mr. Galli also formerly worked at PricewaterhouseCoopers SpA, as Senior Auditor from 1996 to 2002 and Coopers & Lybrand SpA, as Auditor.
Mr. Galli received his undergraduate degree from the University of Bocconi.

Aktive Positionen von Roberto Galli

Unternehmen	Position	Beginn
NEWRON PHARMACEUTICALS S.P.A.	Finanzdirektor/CFO	01.01.2012
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Direktor/Vorstandsmitglied	-
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Roberto Galli

Ehemalige bekannte Positionen von Roberto Galli

Unternehmen	Position	Ende
PricewaterhouseCoopers SpA PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services	Corporate Officer/Principal	01.10.2002
Coopers & Lybrand SpA Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company.	Comptroller/Controller/Auditor	-

Sehen Sie sich die Erfahrung von Roberto Galli im Detail an

Ausbildung von Roberto Galli

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Roberto Galli im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	6
Newron Pharmaceuticals SpA Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system	Health Technology
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Health Technology
University of Bocconi University of Bocconi Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
PricewaterhouseCoopers SpA PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services	Commercial Services
Coopers & Lybrand SpA Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company.	Commercial Services
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	Commercial Services